MLS-222QLD

MLS-222QLD is an investigational **anti-cancer small molecule** being developed by **M-Life** as part of a new class of **multi-targeting agent** therapeutics. Available public descriptions indicate that it is designed to act on both **mitosis** and **apoptosis** pathways in cancer cells, but its precise molecular structure, direct biological targets, and active ingredient have not been publicly disclosed. The compound has been described as having **botanical underpinnings** and has shown reported preclinical activity in **leukemic mouse models** and **in vitro glioblastoma multiforme** models. Public materials link the program primarily to development for **pediatric glioblastoma multiforme** and **acute myeloid leukemia**, with the asset reported to be in **preclinical development** and expected to enter clinical testing around early 2023, although no confirmed later-stage clinical data were identified from the provided context.